Studies on the incorporation of precursors into purine and pyrimidine nucleotides via ‘de novo’ and ‘salvage’ pathways in normal lymphocytes and lymphoblastic cell-line cells

1989 ◽  
Vol 1012 (2) ◽  
pp. 148-155 ◽  
Author(s):  
Yolanda M.T. Marijnen ◽  
Dirk de Korte ◽  
Willem A. Haverkort ◽  
Engelbertus J.S. den Breejen ◽  
Albert H. van Gennip ◽  
...  
1984 ◽  
Vol 160 (4) ◽  
pp. 987-1000 ◽  
Author(s):  
C C Wang ◽  
H W Cheng

Trichomonas vaginalis, a human protozoan parasite known to lack the capability of synthesizing purine and pyrimidine nucleotides de novo, was found also incapable of converting its ribonucleotides to deoxyribonucleotides. The only apparent means of providing deoxyribonucleotides for DNA synthesis relies on salvaging exogenous deoxyribonucleosides by a deoxyribonucleoside phosphotransferase activity in the T. vaginalis 10(5) g pelletable fraction. The activity, constituted by at least two isozymes I and II, can be solubilized by Triton X-100, has a pH optimum of 5.0-6.0, and recognizes only thymidine, deoxyadenosine, deoxyguanosine, and deoxycytidine as the phosphate acceptor. TMP, dAMP, dGMP, dCMP, dUMP, FdUMP, and p-nitrophenylphosphate can serve as phosphate donors. Enzyme I has been purified 10-fold by DEAE-Sepharose chromatography and Sephacryl 200 filtration, and is totally freed of the acid phosphatase of T. vaginalis. It has an estimated molecular weight of 200,000 and Km values of 2-3 mM for the four deoxyribonucleosides, which act on each other as competitive inhibitors. It also possesses phosphatase activity capable of hydrolyzing p-nitrophenylphosphate with a Michaelis constant of 0.74 mM. The rates of hydrolysis are enhanced by thymidine, which suggests that the latter may be the preferred phosphate acceptor, and Enzyme I may be, thus, more a transferase than a phosphatase. This enzyme could be a potential target for antitrichomonial chemotherapy.


1993 ◽  
Vol 293 (1) ◽  
pp. 207-213 ◽  
Author(s):  
W R Pels Rijcken ◽  
B Overdijk ◽  
D H van den Eijnden ◽  
W Ferwerda

Pyrimidine nucleotide metabolism in rat hepatocytes was studied by measurement of the labelling kinetics of the various intermediates after double labelling with [14C]orotic acid and [3H]cytidine, the precursors for the de novo and the salvage pathways respectively. For the uridine nucleotides, differences were found for the 14C/3H ratios in the UDP-sugars, in UMP (of RNA) and in their precursor UTP, suggesting the existence of separated flows of the radioactive precursors through the de novo and the salvage pathways. Higher ratios in the UDP-sugars, which are synthesized in the cytoplasm, and a lower ratio in UMP (of RNA) relative to the 14C/3H ratio in UTP indicated that UTP derived from orotic acid is preferentially used for the cytoplasmic biosynthesis of the UDP-sugars. Uridine, derived from cytidine, is preferentially used for the nuclear-localized synthesis of RNA. In contrast to these findings, the 14C/3H ratios in the cytidine derivatives CMP-NeuAc and CMP (of RNA), and in the liponucleotides CDP-choline and CDP-ethanolamine, were all lower than that in the precursor CTP. This indicates a preferential utilization of the salvage-derived CTP for the synthesis of the liponucleotides as well as for RNA and CMP-NeuAc. Similar conclusions could be drawn from experiments in which the intracellular amounts of several uridine- and cytidine-nucleotide-containing derivatives were increased by preincubating the hepatocytes with unlabelled pyrimidine nucleotides or ethanolamine. Based on these data, we propose a refined model for the intracellular compartmentation of pyrimidine nucleotide biosynthesis in which three pools of UTP are distinguished: a pool of de novo-derived molecules and a pool of salvage-derived molecules, both of which are channelled to the site of utilization; in addition an ‘overflow’ pool exists, consisting of molecules having escaped from channelling. An overflow pool could also be distinguished for CTP, but no discrimination between de novo and salvage-derived molecules could be made.


1978 ◽  
Vol 56 (4) ◽  
pp. 227-236 ◽  
Author(s):  
Herb B. LéJohn ◽  
Linda E. Cameron ◽  
Glen R. Klassen ◽  
Renate U. Meuser

A study of [32P]orthophosphate labelling of purine and pyrimidine nucleotides and dinucleoside polyphosphates, HS3, HS2, and HS1, during ontogeny of the fungus Achlya showed that HS compounds were labelled very quickly at late stages of growth and then declined to low levels just as the overall growth decreased. At this time, sporangial formation was initiated and HS3 increased again. By contrast, the common cellular nucleotides stayed at a low constant level. When 1 mML-glutamine (D-glutamine was ineffective) was added to the growth medium at this time, sporangial formation was aborted.When cells growing in rich medium of peptone, yeast extract, and glucose were transferred to a nutrient-deficient medium of 0.1 mM CaCl2, they developed sporangia within 8 h and sporulated by 10 h. In this period, the cellular levels of HS compounds increased manyfold (HS3, 6-fold, HS2, 18-fold; and HS1, 55-fold). In the presence of 1 mML-glutamine, cellular HS decreased to barely perceptible levels and sporulation was aborted. Several antimetabolites that block de novo biosynthesis of nucleotides, diazouracil, azaserine, and methotrexate, stimulated further HS accumulation in nutrient-deficient medium but did not block sporulation. By contrast, uridine, guanosine, and adenosine caused a partial reduction of HS compounds and correspondingly delayed sporulation. Thymidine was ineffective. Actinomycin D (5 μg/ml) caused HS2 and HS1 to accumulate manyfold and inhibited sporulation. Cycloheximide (10 μg/ml) caused HS3 to increase severaifold and also blocked sporulation, in nutrient-deficient medium, it seemed necessary that all three HS compounds increase simultaneously for sporulation to occur.HS compounds proved to be powerful inhibitors of enzymes involved with nucleic-acid metabolism. They inhibited DNA-dependent RNA polymerases with HS2 being more effective than HS3; HS1 inhibited DNA polymerase specifically. This is probably meaningful as low intracellular levels of HS compounds were detected when nucleic-acid synthesis was proceeding optimally.The uracil moiety of HS compounds was labelled with [14C]aspartate, CO2, and orotate, not uracil or uridine. Neither [14C]adenine nor [14C]adenosine was incorporated into HS3. HS compounds may be biosynthesized by the de novo pathways of nucleotide biosynthesis.A role for HS compounds as 'sensors' of nitrogen insufficiency in Achlya as a prelude to sporulation is suggested by these findings.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2712-2712
Author(s):  
Amy N Sexauer ◽  
Brian Do ◽  
David B Sykes

Acute myeloid leukemia (AML) is an aggressive blood cancer representing ~20% of childhood and ~80% of adult leukemias. Despite advances, treatment has remained the same for decades: cytotoxic chemotherapy with cytarabine combined with an anthracycline. Unfortunately, prognosis remains quite poor, and there is a clear and urgent need for better combination therapies to improve outcomes for AML patients. While a molecularly heterogenous disease, all AML's are characterized by a block in differentiation resulting in the uncontrolled proliferation of immature myeloid elements. "Differentiation therapy," which causes leukemic cells to overcome this block and differentiate into mature myeloid cells lacking leukemia-initiating activity, is an appealing therapeutic approach. It is successfully used in the subset of acute promyelocytic leukemia but has not yet shown success in other leukemia sub-types. Developing differentiation therapy for other leukemias would be an important advance - both agnostic to the genetic background of the leukemia, as well as more effective and better-tolerated than standard chemotherapy. To identify potential compounds which promote myeloid differentiation, our lab previously performed a small molecule screen in an ER-HoxA9 conditionally immortalized murine GMP cell line. One of the identified compounds from the screen which promoted differentiation was an inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme which converts dihydroorotate to orotate as part of the de novo synthesis of the first pyrimidine building block uridine. DHODH is ubiquitously-expressed, and inhibition of DHODH (DHODHi) leads to rapid depletion of uridine, which impacts all metabolites which require uridine as a carrier (e.g. UDP-GlcNAc). The cell's ability to tolerate periods of pyrimidine starvation are dependent on a variety of alternative salvage pathways and are not understood. Several inhibitors of DHODH are clinically available. In a follow up study, we combined the small molecule DHODH inhibitor Brequinar (BRQ) with a genome-wide CRISPR/Cas9 genetic perturbation screen to identify targets and pathways that sensitized cells to the differentiating effects of BRQ (Figure A). This screen was performed both in conditionally immortalized ER-HoxB8 murine GMPs, and in a murine stromal cell line. Across all doses and dosing schedules, unique to the GMP cell line, the most strikingly depleted gene in this screen has been FLT3, indicating that when FLT3 was lost, cells were more sensitized to differentiation by BRQ. The mechanism by which this combination is effective is not currently understood. Preliminary data reveals that the combination of FLT3 inhibition (specifically AC220) and DHODH inhibition in vitro appears to be additive, and possibly synergistic. FLT3 is already an attractive therapeutic target given the frequency of activating mutations and overexpression in AML. In addition, FLT3 signals downstream through STAT5, which is known to function as an important "switch" for malignant transformation in hematopoietic cells in the setting of metabolic stress (Figure B). We hypothesized that the loss of FLT3 signaling and DHODH inhibition independently lead to decreased O-GlcNAcylation and inactivation of STAT3/5, depriving cells of a critical survival signal and sensitizing cells to the metabolic stress of nucleotide deprivation (Figure C). Global metabolic profiling of GMPs and AML cells (both FLT3-WT and FLT3-KO) treated with FLT3i, DHODHi, and the combination is currently underway to understand the impact of these changes on pyrimidine nucleotides, TCA cycle metabolites, and uridine-dependent metabolites. Additional confirmatory studies of STAT3/5 activity and the balance of O-GlcNAcylation (as modulated by DHODH) and phosphorylation (as modulated by FLT3) are also pending, as are the combination studies of FLT3i and DHODHi in our in vivo murine AML model. Disclosures Sykes: Clear Creek Bio: Equity Ownership, Other: Co-Founder.


1984 ◽  
Vol 217 (1) ◽  
pp. 245-252 ◽  
Author(s):  
J Balzarini ◽  
E De Clercq ◽  
D Ayusawa ◽  
T Seno

A thymidylate (dTMP) synthetase-deficient murine mammary carcinoma cell line (FM3A/TS-), auxotrophic for thymidine (dThd), proved extremely useful for studying the dependence of cell growth on the exogenous supply of dThd, the relation between cell growth and DNA synthesis, and the ability of a series of 25 5-substituted 2′-deoxyuridines (dUrd) to substitute for dThd in sustaining cell growth. FM3A/TS-cells did not proliferate unless dThd was supplied to the cell culture medium. The 5-halogenated dUrd derivatives 5-chloro-dUrd, 5-bromo-dUrd and 5-iodo-d Urd also sustained FM3A/TS- cell growth. The extents of incorporation of [methyl-3H]dThd and 5-iodo-[6-3H]dUrd into DNA were closely correlated with their stimulatory effects on FM3A/TS- cell growth. This suggests that the stimulatory effects of the dUrd analogues on the growth rate of FM3A/TS- cells may be considered as evidence for their incorporation into host cell DNA. Based on this premise it is postulated that, in addition to 5-chloro-dUrd, 5-bromo-dUrd, 5-iodo-dUrd and dThd itself, the following dThd analogues are also incorporated into FM3A/TS- cell DNA (in order of the extent to which they are incorporated): 5-hydroxy-dUrd greater than 5-propynyloxy-dUrd greater than 5-ethyl-dUrd greater than 5-ethynyl-dUrd approximately 5-vinyl-dUrd. Thus, the dTMP synthetase-deficient FM3A/TS- cell line represents a unique system to dissociate the de novo and salvage pathways of dTMP biosynthesis and to distinguish those dUrd analogues that are incorporated into DNA from those that are not.


2005 ◽  
Vol 187 (6) ◽  
pp. 2093-2104 ◽  
Author(s):  
Hervé Nicoloff ◽  
Aram Elagöz ◽  
Florence Arsène-Ploetze ◽  
Benoît Kammerer ◽  
Jan Martinussen ◽  
...  

ABSTRACT Carbamoyl phosphate is a precursor for both arginine and pyrimidine biosynthesis. In Lactobacillus plantarum, carbamoyl phosphate is synthesized from glutamine, ATP, and carbon dioxide by two sets of identified genes encoding carbamoyl phosphate synthase (CPS). The expression of the carAB operon (encoding CPS-A) responds to arginine availability, whereas pyrAaAb (encoding CPS-P) is part of the pyrR1BCAaAbDFE operon coding for the de novo pyrimidine pathway repressed by exogenous uracil. The pyr operon is regulated by transcription attenuation mediated by a trans-acting repressor that binds to the pyr mRNA attenuation site in response to intracellular UMP/phosphoribosyl pyrophosphate pools. Intracellular pyrimidine triphosphate nucleoside pools were lower in mutant FB335 (carAB deletion) harboring only CPS-P than in the wild-type strain harboring both CPS-A and CPS-P. Thus, CPS-P activity is the limiting step in pyrimidine synthesis. FB335 is unable to grow in the presence of uracil due to a lack of sufficient carbamoyl phosphate required for arginine biosynthesis. Forty independent spontaneous FB335-derived mutants that have lost regulation of the pyr operon were readily obtained by their ability to grow in the presence of uracil and absence of arginine; 26 harbored mutations in the pyrR1-pyrB loci. One was a prototroph with a deletion of both pyrR1 and the transcription attenuation site that resulted in large amounts of excreted pyrimidine nucleotides and increased intracellular UTP and CTP pools compared to wild-type levels. Low pyrimidine-independent expression of the pyr operon was obtained by antiterminator site-directed mutagenesis. The resulting AE1023 strain had reduced UTP and CTP pools and had the phenotype of a high-CO2-requiring auxotroph, since it was able to synthesize sufficient arginine and pyrimidines only in CO2-enriched air. Therefore, growth inhibition without CO2 enrichment may be due to low carbamoyl phosphate pools from lack of CPS activity.


1984 ◽  
Vol 4 (10) ◽  
pp. 2098-2102
Author(s):  
E Flatau ◽  
F A Gonzales ◽  
L A Michalowsky ◽  
P A Jones

A cell line (T17) was derived from C3H 10T1/2 C18 cells after 17 treatments with increasing concentrations of 5-aza-2'-deoxycytidine. The T17 cell line was very resistant to the cytotoxic effects of 5-aza-2'-deoxycytidine, and the 50% lethal dose for 5-aza-2'-deoxycytidine was ca. 3 microM, which was 30-fold greater than that of the parental C3H 10T1/2 C18 cells. Increased drug resistance was not due to a failure of the T17 cell line to incorporate 5-aza-2'-deoxycytidine into DNA. The cells were also slightly cross-resistant to 5-azacytidine. The percentage of cytosines modified to 5-methylcytosine in T17 cells was 0.7%, a 78% decrease from the level of 3.22% in C3H 10T1/2 C18 cells. The DNA cytosine methylation levels in several clones isolated from the treated lines were on the order of 0.7%, and clones with methylation levels lower than 0.45% were not obtained even after further drug treatments. These highly decreased methylation levels appeared to be unstable, and DNA modification increased as the cells divided in the absence of further drug treatment. The results suggest that it may not be possible to derive mouse cells with vanishingly low levels of 5-methylcytosine and that considerable de novo methylation can occur in cultured lines.


Sign in / Sign up

Export Citation Format

Share Document